On the public citation graph

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

0 signed · 408 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2017.2391openalex-snapshot

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

inferredcites →https://doi.org/10.1016/s1470-2045(15)70122-1openalex-snapshot

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(17)30428-xopenalex-snapshot

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

inferredcites →https://doi.org/10.1056/nejmoa1414428openalex-snapshot

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1503093openalex-snapshot

Pembrolizumab versus Ipilimumab in Advanced Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1609214openalex-snapshot

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

inferredcites →https://doi.org/10.1093/annonc/mdw443openalex-snapshot

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

inferredcites →https://doi.org/10.1159/000453569openalex-snapshot

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

inferredcites →https://doi.org/10.1159/000455014openalex-snapshot

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

inferredcites →https://doi.org/10.1200/jco.2007.12.7837openalex-snapshot

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

inferredcites →https://doi.org/10.1200/jco.2013.31.15_suppl.9011openalex-snapshot

Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab.

inferredcites →https://doi.org/10.1200/jco.2013.53.0105openalex-snapshot

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

inferredcites →https://doi.org/10.1200/jco.2014.60.0379openalex-snapshot

Toxicities of Immunotherapy for the Practitioner

inferredcites →https://doi.org/10.1200/jco.2015.62.9345openalex-snapshot

Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

inferredcites →https://doi.org/10.1200/jco.2015.66.1389openalex-snapshot

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4748520openalex-extracted

Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

inferred← citeshttps://doi.org/10.1001/jamadermatol.2020.2149openalex-snapshot

Association of Anti–Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.1022openalex-snapshot

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.0726openalex-snapshot

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

inferred← citeshttps://doi.org/10.1002/1878-0261.12887openalex-snapshot

Immune response drives outcomes in prostate cancer: implications for immunotherapy

inferred← citeshttps://doi.org/10.1002/9783527845347.ch12openalex-snapshot

NIR Light‐Activated Conversion Nanomaterials for Photothermal/Immunotherapy

inferred← citeshttps://doi.org/10.1002/ajh.25812openalex-snapshot

Recurrent checkpoint inhibitor‐induced warm agglutinin autoimmune hemolytic anemia in a patient with metastatic melanoma

inferred← citeshttps://doi.org/10.1002/cac2.12178openalex-snapshot

Advancing to the era of cancer immunotherapy

inferred← citeshttps://doi.org/10.1002/cam4.5939openalex-snapshot

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients

inferred← citeshttps://doi.org/10.1002/cam4.71694openalex-snapshot

Risk Factors and Comparative Safety of Anti ‐PD ‐1 Combination Therapies in Advanced Melanoma: A Nationwide Real‐World Cohort Study From China

inferred← citeshttps://doi.org/10.1002/cncr.31627openalex-snapshot

Toxicities and outcomes: Do steroids matter?

inferred← citeshttps://doi.org/10.1002/cncr.33153openalex-snapshot

Clinical implications of drug‐induced liver injury in early‐phase oncology clinical trials

inferred← citeshttps://doi.org/10.1002/cncr.33165openalex-snapshot

Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis

inferred← citeshttps://doi.org/10.1002/hep.31227openalex-snapshot

Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

inferred← citeshttps://doi.org/10.1002/hep4.1465openalex-snapshot

Biologic and Checkpoint Inhibitor‐Induced Liver Injury: A Systematic Literature Review

inferred← citeshttps://doi.org/10.1002/ijc.31717openalex-snapshot

Nanoparticle‐based photothermal and photodynamic immunotherapy for tumor treatment

inferred← citeshttps://doi.org/10.1002/ijc.34940openalex-snapshot

Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor

inferred← citeshttps://doi.org/10.1002/iju5.12173openalex-snapshot

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

inferred← citeshttps://doi.org/10.1002/iju5.12181openalex-snapshot

Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

inferred← citeshttps://doi.org/10.1007/978-3-030-02505-2_6openalex-snapshot

Immune-Related Adverse Events: Pneumonitis

inferred← citeshttps://doi.org/10.1007/978-3-030-05070-2_60openalex-snapshot

Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma

inferred← citeshttps://doi.org/10.1007/978-3-030-41008-7_13openalex-snapshot

Immune-Related Adverse Events: Pneumonitis

inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_14openalex-snapshot

Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles

inferred← citeshttps://doi.org/10.1007/978-3-030-64009-5_12openalex-snapshot

Pembrolizumab in Melanoma: From Care to Cure

inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_13openalex-snapshot

Hepatobiliary and Pancreatic Adverse Events

inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_14openalex-snapshot

Pulmonary Toxicities of Immunotherapy

inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_215-1openalex-snapshot

Immunotherapy and Cancer: The Pharmacists’ Perspective

inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_12-1openalex-snapshot

Immune Checkpoint Inhibition

inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_12-2openalex-snapshot

Immune Checkpoint Inhibition

inferred← citeshttps://doi.org/10.1007/978-3-031-00241-0_7openalex-snapshot

Hepatology (Liver and Bile Duct)

inferred← citeshttps://doi.org/10.1007/978-3-031-75480-7_6openalex-snapshot

Immunotherapy for Breast Cancer Survivors: Implications for Clinical Practice

inferred← citeshttps://doi.org/10.1007/978-3-031-83533-9_33openalex-snapshot

Hepatobiliary Toxicity Secondary to Immune Checkpoint Inhibitor Therapy: Early Tocilizumab Treatment to Decouple Steroid Dependency

inferred← citeshttps://doi.org/10.1007/978-3-032-00767-4_215openalex-snapshot

Immunotherapy and Cancer: The Pharmacists’ Perspective

inferred← citeshttps://doi.org/10.1007/978-3-319-46029-1_60-1openalex-snapshot

Managing Checkpoint Inhibitor Symptoms and Toxicity

inferred← citeshttps://doi.org/10.1007/978-981-15-9038-2_9openalex-snapshot

Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics

inferred← citeshttps://doi.org/10.1007/s00092-022-5501-1openalex-snapshot

Immunbedingte Toxizitäten behandeln

inferred← citeshttps://doi.org/10.1007/s00277-021-04429-8openalex-snapshot

Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma

inferred← citeshttps://doi.org/10.1007/s00384-019-03268-4openalex-snapshot

Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike—report of new cases and review of the literature

inferred← citeshttps://doi.org/10.1007/s00432-021-03610-wopenalex-snapshot

Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience

inferred← citeshttps://doi.org/10.1007/s00520-020-05708-2openalex-snapshot

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity

inferred← citeshttps://doi.org/10.1007/s00520-020-05710-8openalex-snapshot

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

inferred← citeshttps://doi.org/10.1007/s10072-022-05920-4openalex-snapshot

Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice

inferred← citeshttps://doi.org/10.1007/s10140-020-01765-6openalex-snapshot

Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients

inferred← citeshttps://doi.org/10.1007/s10147-018-1259-6openalex-snapshot

Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update

inferred← citeshttps://doi.org/10.1007/s10147-021-01872-5openalex-snapshot

The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study

inferred← citeshttps://doi.org/10.1007/s10238-025-01721-zopenalex-snapshot

Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury

inferred← citeshttps://doi.org/10.1007/s10620-022-07689-0openalex-snapshot

Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer

inferred← citeshttps://doi.org/10.1007/s11060-022-03997-7openalex-snapshot

Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review

inferred← citeshttps://doi.org/10.1007/s11684-019-0735-3openalex-snapshot

Advances on immune-related adverse events associated with immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1007/s11864-022-00995-9openalex-snapshot

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

inferred← citeshttps://doi.org/10.1007/s11864-026-01388-yopenalex-snapshot

Review on Photodynamic Therapy Combined with T-Cell Immunotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Mechanisms, Challenges, and Future Directions

inferred← citeshttps://doi.org/10.1007/s11894-020-0752-zopenalex-snapshot

Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives

inferred← citeshttps://doi.org/10.1007/s11894-022-00852-7openalex-snapshot

Update on Immune Checkpoint Inhibitor Enterocolitis

inferred← citeshttps://doi.org/10.1007/s11912-018-0718-6openalex-snapshot

Immune Checkpoint Inhibitor Toxicity

inferred← citeshttps://doi.org/10.1007/s11912-021-01070-6openalex-snapshot

Cardiotoxicity of Immune Checkpoint Inhibitors

inferred← citeshttps://doi.org/10.1007/s11912-022-01241-zopenalex-snapshot

Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review

inferred← citeshttps://doi.org/10.1007/s11936-019-0731-6openalex-snapshot

Cardiotoxicity of Immune Checkpoint Inhibitors

inferred← citeshttps://doi.org/10.1007/s11936-020-00867-1openalex-snapshot

Cardiotoxicity of Contemporary Anticancer Immunotherapy

inferred← citeshttps://doi.org/10.1007/s12032-019-1270-4openalex-snapshot

N-Glycosylation in progression of skin cancer

inferred← citeshttps://doi.org/10.1007/s12094-021-02598-6openalex-snapshot

Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1007/s40257-022-00681-4openalex-snapshot

Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma

inferred← citeshttps://doi.org/10.1007/s40257-022-00706-yopenalex-snapshot

Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors

inferred← citeshttps://doi.org/10.1007/s40264-021-01109-4openalex-snapshot

Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature

inferred← citeshttps://doi.org/10.1007/s40264-025-01540-xopenalex-snapshot

IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials

inferred← citeshttps://doi.org/10.1007/s40278-017-37992-3openalex-snapshot

Immune-related adverse events with resumed anti-PD-1 therapy

inferred← citeshttps://doi.org/10.1007/s40487-019-0096-8openalex-snapshot

A Review of Immune-Mediated Adverse Events in Melanoma

inferred← citeshttps://doi.org/10.1007/s40846-023-00836-6openalex-snapshot

Nanotechnology Potent Photothermal and Photodynamic Immunotherapies of Cancer

inferred← citeshttps://doi.org/10.1016/b978-0-323-67241-2.00019-7openalex-snapshot

Gastrointestinal Toxicities of Immunotherapy

inferred← citeshttps://doi.org/10.1016/b978-0-323-90887-0.00018-3openalex-snapshot

Paraneoplastic neurologic disorders and neurologic complications of immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/b978-3-437-21011-2.00042-9openalex-snapshot

Nierenzellkarzinom

inferred← citeshttps://doi.org/10.1016/b978-3-437-21183-6.00015-5openalex-snapshot

Tumoren der Nieren und der Harnwege

inferred← citeshttps://doi.org/10.1016/b978-3-437-23824-6.00041-9openalex-snapshot

Nierenzellkarzinom

inferred← citeshttps://doi.org/10.1016/b978-3-437-23854-3.00017-8openalex-snapshot

Nierenzellkarzinom

inferred← citeshttps://doi.org/10.1016/j.abd.2023.03.012openalex-snapshot

Psoriasiform rash following maculopapular eruption during the continued administration of pembrolizumab

inferred← citeshttps://doi.org/10.1016/j.abdp.2024.06.001openalex-snapshot

10.1016/j.abdp.2024.06.001

inferred← citeshttps://doi.org/10.1016/j.aed.2025.06.004openalex-snapshot

Rapid Onset of Type 1 Diabetes Mellitus and Destructive Thyroiditis Following Immunotherapy for Metastatic Melanoma

inferred← citeshttps://doi.org/10.1016/j.ajoms.2025.04.011openalex-snapshot

Incidence of oral reactions of immune-related adverse events caused by immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.alit.2022.01.001openalex-snapshot

Immune-related adverse events in various organs caused by immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.annonc.2020.07.004openalex-snapshot

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

inferred← citeshttps://doi.org/10.1016/j.annonc.2020.07.005openalex-snapshot

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

inferred← citeshttps://doi.org/10.1016/j.annonc.2021.03.199openalex-snapshot

Immunotherapy use outside clinical trial populations: never say never?

inferred← citeshttps://doi.org/10.1016/j.annonc.2024.08.2340openalex-snapshot

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study

inferred← citeshttps://doi.org/10.1016/j.annonc.2024.09.007openalex-snapshot

Breaking the link: IL-6 targeting to uncouple toxicity and efficacy in patients treated with immune checkpoint blockade

inferred← citeshttps://doi.org/10.1016/j.aohep.2021.100561openalex-snapshot

Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience

inferred← citeshttps://doi.org/10.1016/j.berh.2020.101511openalex-snapshot

Immunologic adverse events from immune checkpoint therapy

inferred← citeshttps://doi.org/10.1016/j.biomaterials.2020.120407openalex-snapshot

Improving safety of cancer immunotherapy via delivery technology

inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.109477openalex-snapshot

Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo

inferred← citeshttps://doi.org/10.1016/j.bpg.2020.101703openalex-snapshot

Immunotherapy induced enterocolitis and gastritis – What to do and when?

inferred← citeshttps://doi.org/10.1016/j.bulcan.2020.07.009openalex-snapshot

Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients

inferred← citeshttps://doi.org/10.1016/j.canlet.2024.217241openalex-snapshot

Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions

inferred← citeshttps://doi.org/10.1016/j.canlet.2025.218203openalex-snapshot

Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions

inferred← citeshttps://doi.org/10.1016/j.cej.2025.160294openalex-snapshot

Mesoporous dual-atom nanozyme induced cuproptosis and apoptosis for boosting immunogenic cell death along with reprogramming tumor immune-suppressive microenvironment

inferred← citeshttps://doi.org/10.1016/j.cell.2021.02.011openalex-snapshot

Understanding and treating the inflammatory adverse events of cancer immunotherapy

inferred← citeshttps://doi.org/10.1016/j.cell.2021.09.020openalex-snapshot

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

inferred← citeshttps://doi.org/10.1016/j.cgh.2020.01.033openalex-snapshot

Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review

inferred← citeshttps://doi.org/10.1016/j.cgh.2022.03.050openalex-snapshot

Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study

inferred← citeshttps://doi.org/10.1016/j.chest.2018.08.1048openalex-snapshot

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1016/j.clcc.2023.12.003openalex-snapshot

Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors

inferred← citeshttps://doi.org/10.1016/j.clindermatol.2019.10.015openalex-snapshot

The life-threatening eruptions of immune checkpoint inhibitor therapy

inferred← citeshttps://doi.org/10.1016/j.clindermatol.2020.06.011openalex-snapshot

Cutaneous immune-related adverse events to checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.cllc.2020.04.013openalex-snapshot

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients

inferred← citeshttps://doi.org/10.1016/j.cllc.2022.07.015openalex-snapshot

Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events

inferred← citeshttps://doi.org/10.1016/j.clon.2021.06.009openalex-snapshot

Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort

inferred← citeshttps://doi.org/10.1016/j.cpccr.2020.100031openalex-snapshot

Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2018.06.016openalex-snapshot

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.102816openalex-snapshot

Current opinions in immune checkpoint inhibitors rechallenge in solid cancers

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103354openalex-snapshot

Managing side effects of immune checkpoint inhibitors in breast cancer

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103434openalex-snapshot

Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103579openalex-snapshot

Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature

inferred← citeshttps://doi.org/10.1016/j.ctrv.2026.103121openalex-snapshot

Hematological immune-related adverse events associated with checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.dld.2025.02.027openalex-snapshot

Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies

inferred← citeshttps://doi.org/10.1016/j.ejca.2018.10.006openalex-snapshot

Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejca.2019.04.026openalex-snapshot

Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy

inferred← citeshttps://doi.org/10.1016/j.ejca.2019.09.022openalex-snapshot

Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejca.2019.12.015openalex-snapshot

Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome

inferred← citeshttps://doi.org/10.1016/j.ejca.2020.02.010openalex-snapshot

The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study

inferred← citeshttps://doi.org/10.1016/j.ejca.2021.04.045openalex-snapshot

Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy

inferred← citeshttps://doi.org/10.1016/j.ejca.2021.05.041openalex-snapshot

Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation

inferred← citeshttps://doi.org/10.1016/j.ejca.2021.08.026openalex-snapshot

Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study

inferred← citeshttps://doi.org/10.1016/j.ejca.2023.03.025openalex-snapshot

Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus

inferred← citeshttps://doi.org/10.1016/j.ejca.2026.116890openalex-snapshot

Successful rechallenge of immune checkpoint inhibitor after immune-related myocarditis, myositis, myasthenia gravis overlap syndrome (IM3OS)

inferred← citeshttps://doi.org/10.1016/j.gastre.2023.10.003openalex-snapshot

Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

inferred← citeshttps://doi.org/10.1016/j.gastrohep.2023.10.009openalex-snapshot

Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

inferred← citeshttps://doi.org/10.1016/j.gie.2019.09.009openalex-snapshot

Immune checkpoint inhibitor–related luminal GI adverse events

inferred← citeshttps://doi.org/10.1016/j.hoc.2021.11.002openalex-snapshot

Immunotherapy-associated Autoimmune Hemolytic Anemia

inferred← citeshttps://doi.org/10.1016/j.ijcard.2020.08.024openalex-snapshot

Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy

inferred← citeshttps://doi.org/10.1016/j.intimp.2022.108803openalex-snapshot

Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer

inferred← citeshttps://doi.org/10.1016/j.intimp.2024.113559openalex-snapshot

Insight of immune checkpoint inhibitor related myocarditis

inferred← citeshttps://doi.org/10.1016/j.intimp.2026.116801openalex-snapshot

Mechanistic insights and therapeutic innovation in immune-related adverse events

inferred← citeshttps://doi.org/10.1016/j.iotech.2024.100704openalex-snapshot

Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities

inferred← citeshttps://doi.org/10.1016/j.jaccao.2020.11.012openalex-snapshot

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity

inferred← citeshttps://doi.org/10.1016/j.jaci.2022.08.028openalex-snapshot

Drug allergy: A 2022 practice parameter update

inferred← citeshttps://doi.org/10.1016/j.jaip.2020.06.028openalex-snapshot

Balancing Cancer Immunotherapy Efficacy and Toxicity

inferred← citeshttps://doi.org/10.1016/j.jaut.2020.102514openalex-snapshot

Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development

inferred← citeshttps://doi.org/10.1016/j.jcrc.2026.155655openalex-snapshot

Intensive care admissions for severe immune-related adverse events associated with immune checkpoint inhibitor therapy: a 10-year cohort study

inferred← citeshttps://doi.org/10.1016/j.jhepr.2020.100170openalex-snapshot

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.jns.2021.117424openalex-snapshot

Neurological complications of immune checkpoint inhibitor cancer immunotherapy

inferred← citeshttps://doi.org/10.1016/j.lpm.2025.104326openalex-snapshot

Gastrointestinal complications of immune checkpoint Inhibitor therapy

inferred← citeshttps://doi.org/10.1016/j.lungcan.2021.08.019openalex-snapshot

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

inferred← citeshttps://doi.org/10.1016/j.matdes.2022.110656openalex-snapshot

Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy

inferred← citeshttps://doi.org/10.1016/j.medcle.2020.06.030openalex-snapshot

Toxicities from immunotherapy: From clinical trials to real-world clinical practice

inferred← citeshttps://doi.org/10.1016/j.medcli.2020.06.057openalex-snapshot

Toxicities from immunotherapy: From clinical trials to real-world clinical practice

inferred← citeshttps://doi.org/10.1016/j.omto.2020.11.001openalex-snapshot

Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance

inferred← citeshttps://doi.org/10.1016/j.resinv.2025.07.023openalex-snapshot

Immune checkpoint inhibitor-related pneumonitis: From guidelines to the front lines

inferred← citeshttps://doi.org/10.1016/j.revmed.2019.09.005openalex-snapshot

Toxicités immunologiques induites par les inhibiteurs de checkpoint en 2019 : mise au point

inferred← citeshttps://doi.org/10.1016/j.rmcr.2019.100979openalex-snapshot

A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab

inferred← citeshttps://doi.org/10.1016/j.semcancer.2019.06.012openalex-snapshot

Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review

inferred← citeshttps://doi.org/10.1016/j.suronc.2019.01.002openalex-snapshot

Revolutionizing treatment of advanced melanoma with immunotherapy

inferred← citeshttps://doi.org/10.1016/j.tcm.2022.10.005openalex-snapshot

Editorial commentary: Immune checkpoint inhibitors and the cardiovascular system: Reflecting on the past and looking towards the future

inferred← citeshttps://doi.org/10.1016/j.urology.2019.04.031openalex-snapshot

Advanced Bladder Cancer Rechallenged With an Immune Checkpoint Inhibitor: A Case Report

inferred← citeshttps://doi.org/10.1016/j.urolonc.2025.10.021openalex-snapshot

Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter study

inferred← citeshttps://doi.org/10.1016/j.ymeth.2022.07.004openalex-snapshot

Applicability analysis of immunotherapy for lung cancer patients based on deep learning

inferred← citeshttps://doi.org/10.1016/s0140-6736(21)01206-xopenalex-snapshot

Immune checkpoint inhibitors in melanoma

inferred← citeshttps://doi.org/10.1016/s0140-6736(23)00821-8openalex-snapshot

Cutaneous melanoma

inferred← citeshttps://doi.org/10.1016/s1470-2045(18)30700-9openalex-snapshot

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

inferred← citeshttps://doi.org/10.1016/s1470-2045(20)30107-8openalex-snapshot

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research

inferred← citeshttps://doi.org/10.1016/s1877-1203(20)30147-6openalex-snapshot

Place de l’immuno-oncologie chez les patients ayant reçu des IO : quid du « rechallenge » ?

inferred← citeshttps://doi.org/10.1016/s1877-1203(21)00108-7openalex-snapshot

Questions pratiques en immunothérapie dans le cancer bronchique non à petites cellules : dose, durée, rythme de traitement, réintroduction

inferred← citeshttps://doi.org/10.1016/s1877-1203(21)00118-xopenalex-snapshot

Gestion des toxicités de l’immunothérapie

inferred← citeshttps://doi.org/10.1016/s2213-2600(18)30172-3openalex-snapshot

Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy

inferred← citeshttps://doi.org/10.1016/s2468-1253(20)30014-5openalex-snapshot

British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis

inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c01684openalex-snapshot

Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment

inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c00370openalex-snapshot

Design, Synthesis, and Evaluation of o -(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo

inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c01355openalex-snapshot

Design, Synthesis, and Biological Evaluation of Small-Molecule-Based Radioligands with Improved Pharmacokinetic Properties for Imaging of Programmed Death Ligand 1

inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c02362openalex-snapshot

Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy

inferred← citeshttps://doi.org/10.1021/acsmedchemlett.6c00048openalex-snapshot

Design, Synthesis and Biological Evaluation of Oxadiazole-Biphenyl Derivatives as Small Molecule Inhibitors Targeting PD-1/PD-L1 Immune Checkpoint

inferred← citeshttps://doi.org/10.1038/s41571-021-00597-8openalex-snapshot

Harnessing big data to characterize immune-related adverse events

inferred← citeshttps://doi.org/10.1038/s41571-022-00600-wopenalex-snapshot

Immune-checkpoint inhibitors: long-term implications of toxicity

inferred← citeshttps://doi.org/10.1038/s41572-020-0160-6openalex-snapshot

Immune-related adverse events of checkpoint inhibitors

inferred← citeshttps://doi.org/10.1038/s41582-024-01001-6openalex-snapshot

Peripheral nervous system immune-related adverse events due to checkpoint inhibition

inferred← citeshttps://doi.org/10.1039/d3tb02842aopenalex-snapshot

Recent advances in light-triggered cancer immunotherapy

inferred← citeshttps://doi.org/10.1039/d4ra06965jopenalex-snapshot

Biomimetic nanoparticles with red blood cell membranes for enhanced photothermal and immunotherapy for tumors

inferred← citeshttps://doi.org/10.1055/s-0038-1667358openalex-snapshot

Liver Toxicity with Cancer Checkpoint Inhibitor Therapy

inferred← citeshttps://doi.org/10.1080/14397595.2018.1532559openalex-snapshot

Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy

inferred← citeshttps://doi.org/10.1080/14737140.2019.1562342openalex-snapshot

Management of immune-related adverse events resulting from immune checkpoint blockade

inferred← citeshttps://doi.org/10.1080/14737140.2021.1996230openalex-snapshot

Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy

inferred← citeshttps://doi.org/10.1080/14737140.2025.2517274openalex-snapshot

Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes

inferred← citeshttps://doi.org/10.1080/14796694.2025.2500918openalex-snapshot

A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS)

inferred← citeshttps://doi.org/10.1080/17425255.2019.1574744openalex-snapshot

Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies

inferred← citeshttps://doi.org/10.1080/1750743x.2024.2383557openalex-snapshot

The development of anti-PD-1 antibody-induced spinal cord injury in bone marrow transplant C57BL/6 Rag1 -/- mouse model

inferred← citeshttps://doi.org/10.1080/1750743x.2025.2473305openalex-snapshot

Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management

inferred← citeshttps://doi.org/10.1080/17843286.2021.1903662openalex-snapshot

Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key

inferred← citeshttps://doi.org/10.1080/2162402x.2018.1524695openalex-snapshot

Clinical characterization of colitis arising from anti-PD-1 based therapy

inferred← citeshttps://doi.org/10.1080/2162402x.2021.1875639openalex-snapshot

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1080/21691401.2022.2131354openalex-snapshot

Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis

inferred← citeshttps://doi.org/10.1088/1361-6528/ab884dopenalex-snapshot

Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy

inferred← citeshttps://doi.org/10.1093/jcag/gwab019openalex-snapshot

Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort

inferred← citeshttps://doi.org/10.1093/jjco/hyae067openalex-snapshot

The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1093/jjco/hyaf200openalex-snapshot

Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review

inferred← citeshttps://doi.org/10.1093/oncolo/oyae134openalex-snapshot

Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1093/rheumatology/keab249openalex-snapshot

Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study

inferred← citeshttps://doi.org/10.1097/cad.0000000000000957openalex-snapshot

Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients

inferred← citeshttps://doi.org/10.1097/cco.0000000000000681openalex-snapshot

Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice

inferred← citeshttps://doi.org/10.1097/cji.0000000000000268openalex-snapshot

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey

inferred← citeshttps://doi.org/10.1097/cji.0000000000000337openalex-snapshot

Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer

inferred← citeshttps://doi.org/10.1097/cji.0000000000000383openalex-snapshot

Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies

inferred← citeshttps://doi.org/10.1097/cmr.0000000000000730openalex-snapshot

Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma

inferred← citeshttps://doi.org/10.1097/hc9.0000000000000525openalex-snapshot

Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: A systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1097/hep.0000000000000045openalex-snapshot

Checkpoint inhibitor hepatotoxicity: pathogenesis and management

inferred← citeshttps://doi.org/10.1097/md.0000000000012937openalex-snapshot

Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma

showing the first 200 of 391 · page through all 391

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.